Capital Commitment

Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

Read More


Review article

Potential of Pan-RGD integrin antagonists for treatment of retinal vascular disorders

Read more



OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

Read the full press release



Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

Read more


Our mission

To prevent vision loss and address unmet medical needs in retinal disorders

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Advancing Science. Enhancing Vision.

Oxurion builds on a yearlong expertise and knowledge platform resulting from local and international scientific collaboration. In today’s rebranding, we further embrace our core expertise and evoke our aspirations for the future. As before, we are driven by the ambition to expand our activities, building on our past, into new areas.

We are advancing our pipeline of disease-modifying drug candidates to preserve vision for patients with back of the eye disorders and look forward to sharing the progress of our clinical programs.

- Patrik De Haes, MD, CEO of Oxurion


3 reasons why we need to raise diabetic eye disease awareness

Read full story

Join forces to fight eye disease in developing countries

Read full story

9 striking facts about diabetic eye disease

Read full story


Oxurion employs 77 people worldwide, all are united by a shared goal: to make Oxurion a global leader in developing and commercializing innovative treatments for chronic eye disorders. Want to join us?

Visit our careers site


Oxurion relies on a network of experienced partners to bring the best possible eye care to patients across the globe. We are always open to new opportunities for partnership and collaboration for improving eye care.

Want to become a partner? Contact us!

Stay in touch

Be sure to check in regularly for the latest news about our our company, research & development activities and updates for investors or just subscribe to our mailing list to receive regular updates.

Read our latest news or Subscribe